Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Overview | 8 | 1 |
| Therapeutics Development | 9 | 1 |
| Pipeline Products for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Overview | 9 | 1 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics under Development by Companies | 10 | 1 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Pipeline Products Glance | 11 | 4 |
| Late Stage Products | 11 | 1 |
| Clinical Stage Products | 12 | 1 |
| Early Stage Products | 13 | 1 |
| Unknown Stage Products | 14 | 1 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Products under Development by Companies | 15 | 1 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Companies Involved in Therapeutics Development | 16 | 10 |
| Bionovis SA | 16 | 1 |
| Bristol-Myers Squibb Company | 17 | 1 |
| ChemoCentryx, Inc. | 18 | 1 |
| Coherus BioSciences, Inc. | 19 | 1 |
| Genor BioPharma Co., Ltd. | 20 | 1 |
| GlaxoSmithKline Plc | 21 | 1 |
| KPI Therapeutics, Inc. | 22 | 1 |
| Panacea Biotec Limited | 23 | 1 |
| Sandoz International GmbH | 24 | 1 |
| The International Biotechnology Center (IBC) Generium | 25 | 1 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Therapeutics Assessment | 26 | 9 |
| Assessment by Monotherapy Products | 26 | 1 |
| Assessment by Target | 27 | 2 |
| Assessment by Mechanism of Action | 29 | 2 |
| Assessment by Route of Administration | 31 | 2 |
| Assessment by Molecule Type | 33 | 2 |
| Drug Profiles | 35 | 34 |
| abatacept Drug Profile | 35 | 5 |
| belimumab Drug Profile | 40 | 6 |
| CCX-168 Drug Profile | 46 | 5 |
| dalazatide Drug Profile | 51 | 5 |
| mepolizumab Drug Profile | 56 | 5 |
| rituximab biosimilar Drug Profile | 61 | 2 |
| rituximab biosimilar Drug Profile | 63 | 1 |
| rituximab biosimilar Drug Profile | 64 | 1 |
| rituximab biosimilar Drug Profile | 65 | 1 |
| rituximab biosimilar Drug Profile | 66 | 1 |
| rituximab biosimilar Drug Profile | 67 | 1 |
| rituximab biosimilar Drug Profile | 68 | 1 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Dormant Projects | 69 | 1 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Discontinued Products | 70 | 1 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Product Development Milestones | 71 | 15 |
| Featured News &Press Releases | 71 | 1 |
| Jun 16, 2016: ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development | 71 | 1 |
| Jun 01, 2016: ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis | 72 | 1 |
| May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress | 73 | 2 |
| Apr 28, 2016: ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis | 75 | 1 |
| Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 | 76 | 2 |
| Nov 09, 2015: Kineta Presents New Data Demonstrating Positive, Predictive Responses to Dalazatide in Psoriasis Patients and in Lupus, ANCA Vasculitis Studies at American College of Rheumatology Annual Meeting | 78 | 1 |
| Apr 21, 2015: Kineta, University of Groningen Present New, Positive Data for Dalazatide in ANCA Vasculitis, an Orphan Disease | 78 | 1 |
| Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vascul... | 79 | 1 |
| Nov 17, 2014: ChemoCentryx's Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements | 80 | 1 |
| Jun 02, 2014: ChemoCentryx's Orally-Administered Complement 5a Receptor Inhibitor, CCX168, Shows Benefit in ANCA-Associated Vasculitis Based on Birmingham Vasculitis Activity Score and Renal Disease Measurements | 81 | 1 |
| Feb 14, 2014: GSK announces start of Phase lll study for mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis | 82 | 1 |
| Dec 03, 2013: ChemoCentryx Announces Positive Top-Line CCX168 Phase II Data in ANCA-Associated Renal Vasculitis | 83 | 1 |
| Nov 10, 2010: ChemoCentryx Presents Positive Phase I Results For CCX168 At Annual American College Of Rheumatology Meeting | 84 | 2 |
| Appendix | 86 | 2 |
| Methodology | 86 | 1 |
| Coverage | 86 | 1 |
| Secondary Research | 86 | 1 |
| Primary Research | 86 | 1 |
| Expert Panel Validation | 86 | 1 |
| Contact Us | 86 | 1 |
| Disclaimer | 87 | 1 |
